Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 mai 2017 02h00 HE | Source: Motif BioSciences Inc.

Motif Bio Appoints Scientific Opinion Leaders to Advisory Board

NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the...
05 mai 2017 02h00 HE | Source: Motif BioSciences Inc.

Motif Bio Appoints Dr. Craig Albanese as Non-Executive Director

NEW YORK, May 05, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the...
01 mai 2017 16h30 HE | Source: Motif BioSciences Inc.

Motif Bio Reports Year-End 2016 Financial Results

NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced...
01 mai 2017 16h30 HE | Source: Motif BioSciences Inc.

Motif Bio Reports Year-End 2016 Financial Results

NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced...
18 avr. 2017 02h00 HE | Source: Motif BioSciences Inc.

Motif Bio Announces Positive Results for Iclaprim, in the REVIVE-1 Phase 3 Study

Iclaprim met the primary endpoint Iclaprim was well tolerated in the study Data from the second Phase 3 ABSSSI Trial, REVIVE-2, expected in the second half of 2017 NDA submission...
30 janv. 2017 18h39 HE | Source: Motif BioSciences Inc.

Motif Bio Phase 3 Clinical Trial Finishes Patient Treatment Phase

NEW YORK, Jan. 30, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today...
17 janv. 2017 16h03 HE | Source: Motif BioSciences Inc.

Appointment of Chief Financial Officer

NEW YORK, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, announces...
22 déc. 2016 08h48 HE | Source: Motif BioSciences Inc.

Motif Bio plc Announces Conversion of Convertible Promissory Notes, PDMR Dealing and Total Voting Rights

NEW YORK, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, announced...
23 nov. 2016 11h49 HE | Source: Motif BioSciences Inc.

Motif Bio plc Announces Closing of its $25 Million U.S. Initial Public Offering and European Placement

NEW YORK, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics,...
18 nov. 2016 08h46 HE | Source: Motif BioSciences Inc.

Motif Bio plc Announces Pricing Of $25 Million U.S. Initial Public Offering and European Placing

NEW YORK, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif)(NASDAQ:MTFB), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the pricing...

Page précédente